Kenvue Inc. (NYSE:KVUE) Holdings Raised by DnB Asset Management AS

DnB Asset Management AS lifted its stake in Kenvue Inc. (NYSE:KVUE) by 6.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 381,232 shares of the company’s stock after purchasing an additional 22,590 shares during the quarter. DnB Asset Management AS’s holdings in Kenvue were worth $8,139,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of KVUE. Norges Bank acquired a new position in shares of Kenvue in the fourth quarter worth about $521,348,000. State Street Corp lifted its position in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after acquiring an additional 18,283,473 shares in the last quarter. Boston Partners boosted its stake in Kenvue by 36.9% in the 4th quarter. Boston Partners now owns 23,595,963 shares of the company’s stock worth $503,145,000 after purchasing an additional 6,366,097 shares during the period. Holocene Advisors LP grew its position in Kenvue by 75.5% during the 3rd quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock worth $321,194,000 after purchasing an additional 5,975,392 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Kenvue during the 4th quarter valued at $98,926,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

KVUE has been the topic of a number of research analyst reports. Piper Sandler lifted their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Evercore ISI started coverage on Kenvue in a research note on Monday, March 24th. They set an “in-line” rating and a $25.00 target price on the stock. UBS Group reduced their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Canaccord Genuity Group boosted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $24.00.

Kenvue Stock Up 1.0 %

KVUE opened at $23.74 on Friday. The firm has a market cap of $45.36 billion, a P/E ratio of 44.78, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business has a 50 day moving average price of $22.32 and a 200 day moving average price of $22.45. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.45%. Kenvue’s dividend payout ratio is presently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.